Paper Details

  1. Home
  2. Paper Details

Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.

Author: Ghasemi-PirbalutiMasoumeh, MotaghiEhsan, ZabihiMohsen

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This meta-analysis compared the efficacy and safety of etrolizumab and infliximab in moderate to severe ulcerative colitis. Seven trials showed no significant differences in clinical remission and serious adverse events between etrolizumab and infliximab. Etrolizumab had significantly fewer adverse events than infliximab. Further trials are needed to compare other parameters of efficacy, such as clinical response and mucosal healing.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: There is still a need to develop new effective medications for the treatment of ulcerative colitis, particularly for patients who are intolerant or resistant to first line therapies. This article compared the efficacy and safety of etrolizumab and infliximab in moderate to severe ulcerat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.phrs.2018.11.003

データ提供：米国国立医学図書館（NLM）

Etrolizumab vs. Infliximab: A Duel in the Ulcerative Colitis Desert

Ulcerative colitis, like a treacherous desert, can leave patients feeling lost and parched. This meta-analysis, using [Bucher's method] to compare [etrolizumab and infliximab], acts like a compass guiding us through the complexities of [ulcerative colitis] treatment. The authors found that [etrolizumab and infliximab] exhibited [comparable efficacy and safety] in the treatment of [ulcerative colitis].

A New Direction in Ulcerative Colitis Treatment

This meta-analysis suggests that [etrolizumab] might be a viable alternative to [infliximab] for patients with [ulcerative colitis]. It's like finding a new oasis in the desert, offering a different perspective on how we might manage this challenging disease.

Finding Balance in the Ulcerative Colitis Desert

Remember, even the most promising treatment options, like a shimmering oasis in the desert, should be viewed with a critical eye. Always consult with your doctor to determine the best course of treatment for you, taking into account your individual needs and health history.

Dr.Camel's Conclusion

This meta-analysis, like a caravan exploring a new route across the desert, reveals the promise of [etrolizumab] as a potential treatment for [ulcerative colitis]. While [etrolizumab] and [infliximab] have demonstrated similar efficacy, it's crucial to find the right oasis for your individual needs. Navigating the desert of [ulcerative colitis] is a personal journey, and a collaborative partnership with your doctor is essential.

Date :
  1. Date Completed 2019-05-13
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30395950

DOI: Digital Object Identifier

10.1016/j.phrs.2018.11.003

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.